<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gao C</submitter><funding>National Natural Science Foundation of China</funding><funding>Tianjin Binhai New Area Health Commission Science-technology Innovation Plan Projects</funding><pagination>241</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7301524</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Mesenchymal stem cells (MSCs) have become a promising candidate for cell-based immune therapy for acute rejection (AR) after heart transplantation due to possessing immunomodulatory properties. In this study, we evaluated the efficacy of soluble fibronectin-like protein 2 (sFgl2) overexpressing mesenchymal stem cells (sFgl2-MSCs) in inhibiting AR of heart transplantation in mice by regulating immune tolerance through inducing M2 phenotype macrophage polarization.&lt;h4>Methods and results&lt;/h4>The sFgl2, a novel immunomodulatory factor secreted by regulatory T cells, was transfected into MSCs to enhance their immunosuppressive functions. After being co-cultured for 72 h, the sFgl2-MSCs inhibited M1 polarization whereas promoted M2 of polarization macrophages through STAT1 an</pubmed_abstract><journal>Stem cell research &amp; therapy</journal><pubmed_title>Mesenchymal stem cells transfected with sFgl2 inhibit the acute rejection of heart transplantation in mice by regulating macrophage activation.</pubmed_title><pmcid>PMC7301524</pmcid><funding_grant_id>2017BWKY036</funding_grant_id><funding_grant_id>81570375</funding_grant_id><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Li Z</pubmed_authors><pubmed_authors>Chen M</pubmed_authors><pubmed_authors>Lu J</pubmed_authors><pubmed_authors>Qi F</pubmed_authors><pubmed_authors>Jia H</pubmed_authors><pubmed_authors>Li P</pubmed_authors><pubmed_authors>Du X</pubmed_authors><pubmed_authors>Wang X</pubmed_authors><pubmed_authors>Chang Y</pubmed_authors><pubmed_authors>Zhang B</pubmed_authors><pubmed_authors>Gao C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Mesenchymal stem cells transfected with sFgl2 inhibit the acute rejection of heart transplantation in mice by regulating macrophage activation.</name><description>&lt;h4>Background&lt;/h4>Mesenchymal stem cells (MSCs) have become a promising candidate for cell-based immune therapy for acute rejection (AR) after heart transplantation due to possessing immunomodulatory properties. In this study, we evaluated the efficacy of soluble fibronectin-like protein 2 (sFgl2) overexpressing mesenchymal stem cells (sFgl2-MSCs) in inhibiting AR of heart transplantation in mice by regulating immune tolerance through inducing M2 phenotype macrophage polarization.&lt;h4>Methods and results&lt;/h4>The sFgl2, a novel immunomodulatory factor secreted by regulatory T cells, was transfected into MSCs to enhance their immunosuppressive functions. After being co-cultured for 72 h, the sFgl2-MSCs inhibited M1 polarization whereas promoted M2 of polarization macrophages through STAT1 an</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jun</publication><modification>2025-04-21T21:09:47.445Z</modification><creation>2020-06-25T07:31:39Z</creation></dates><accession>S-EPMC7301524</accession><cross_references><pubmed>32552823</pubmed><doi>10.1186/s13287-020-01752-1</doi></cross_references></HashMap>